• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Trinity Capital Inc. Provides $45 Million in Growth Capital to Rapid Micro Biosystems, Modernizing Healthcare Industry Practices

    9/22/25 8:00:00 AM ET
    $RPID
    $TRIN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Finance: Consumer Services
    Finance
    Get the next $RPID alert in real time by email

    PHOENIX, Sept. 22, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $45 million in growth capital to Rapid Micro Biosystems (NASDAQ:RPID) ("Rapid Micro"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products.

    (PRNewsfoto/Trinity Capital Inc.)

    Rapid Micro specializes in automating microbial quality control in mission-critical applications such as environmental monitoring, water testing, sterility testing, and bioburden testing. The Company's Growth Direct® platform provides faster results, greater accuracy, increased operational efficiency, and stronger data integrity, enabling customers to make quicker decisions that help ensure a safe and consistent supply of important healthcare products.

    "In an industry where quality cannot be compromised, Rapid Micro Biosystems is delivering the automation and dependability manufacturers need," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital. "They are transforming a critical process within biopharma manufacturing, and we are proud to partner with a team driving meaningful impact across the industry."

    This new capital will help scale Rapid Micro's operations, to include supporting the continued global commercial expansion of the Growth Direct platform, and ongoing investments to drive gross margin expansion through product cost reduction, increased manufacturing efficiencies, and service productivity.

    "We are pleased to partner with Trinity Capital, who shares our vision of automating manual microbial quality control testing methods used in biopharma manufacturing," said Robert Spignesi, President and CEO of Rapid Micro Biosystems. "This facility significantly strengthens our financial position and supports our continued focus on long-term revenue growth, margin expansion, and increasing shareholder value."

    About Trinity Capital Inc.

    Trinity Capital Inc. (NASDAQ:TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $4.7 billion across over 420 investments since inception in 2008 (As of June 30, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

    About Rapid Micro Biosystems

    Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-45-million-in-growth-capital-to-rapid-micro-biosystems-modernizing-healthcare-industry-practices-302562036.html

    SOURCE Trinity Capital Inc.

    Get the next $RPID alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RPID
    $TRIN

    CompanyDatePrice TargetRatingAnalyst
    Rapid Micro Biosystems Inc.
    $RPID
    7/28/2025$8.00Buy
    Lake Street
    Trinity Capital Inc.
    $TRIN
    5/13/2025$16.00Buy
    B. Riley Securities
    Rapid Micro Biosystems Inc.
    $RPID
    2/12/2025$8.00Overweight
    KeyBanc Capital Markets
    Trinity Capital Inc.
    $TRIN
    12/2/2024$13.00Equal Weight → Underweight
    Wells Fargo
    Trinity Capital Inc.
    $TRIN
    8/22/2023$15.50Neutral → Buy
    Compass Point
    Trinity Capital Inc.
    $TRIN
    8/7/2023$15.00Underperform → Mkt Perform
    Keefe Bruyette
    Trinity Capital Inc.
    $TRIN
    7/5/2023$15.00Buy
    Jefferies
    Trinity Capital Inc.
    $TRIN
    3/13/2023$13.50 → $11.00Mkt Perform → Underperform
    Keefe Bruyette
    More analyst ratings

    $RPID
    $TRIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President and CIO Brown Kyle Steven bought $99,925 worth of shares (6,920 units at $14.44), increasing direct ownership by 0.70% to 997,033 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    11/12/25 9:32:09 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Executive Chairman Brown Steve Louis bought $87,930 worth of shares (6,100 units at $14.41), increasing direct ownership by 0.55% to 818,466 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    11/10/25 8:40:26 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Director Estes Ronald E. bought $28,880 worth of shares (2,000 units at $14.44), increasing direct ownership by 5% to 38,779 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    11/10/25 4:38:36 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    SEC Filings

    View All

    SEC Form 10-Q filed by Rapid Micro Biosystems Inc.

    10-Q - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    11/7/25 5:06:51 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rapid Micro Biosystems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Filer)

    11/7/25 6:03:42 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Trinity Capital Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Trinity Capital Inc. (0001786108) (Filer)

    11/6/25 8:00:30 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, President and CIO Brown Kyle Steven bought $99,925 worth of shares (6,920 units at $14.44), increasing direct ownership by 0.70% to 997,033 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    11/12/25 9:32:09 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Executive Chairman Brown Steve Louis bought $87,930 worth of shares (6,100 units at $14.41), increasing direct ownership by 0.55% to 818,466 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    11/10/25 8:40:26 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Director Estes Ronald E. bought $28,880 worth of shares (2,000 units at $14.44), increasing direct ownership by 5% to 38,779 units (SEC Form 4)

    4 - Trinity Capital Inc. (0001786108) (Issuer)

    11/10/25 4:38:36 PM ET
    $TRIN
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Rapid Micro Biosystems with a new price target

    Lake Street initiated coverage of Rapid Micro Biosystems with a rating of Buy and set a new price target of $8.00

    7/28/25 8:29:57 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    B. Riley Securities resumed coverage on Trinity Capital with a new price target

    B. Riley Securities resumed coverage of Trinity Capital with a rating of Buy and set a new price target of $16.00

    5/13/25 10:05:49 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    KeyBanc Capital Markets initiated coverage on Rapid Micro Biosystems with a new price target

    KeyBanc Capital Markets initiated coverage of Rapid Micro Biosystems with a rating of Overweight and set a new price target of $8.00

    2/12/25 7:09:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Leadership Updates

    Live Leadership Updates

    View All

    Trinity Capital Inc. Expands Life Sciences Vertical with Appointment of Paul D'Agrosa

    PHOENIX, Oct. 8, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the appointment of Paul D'Agrosa as Managing Director of Life Sciences, based in Denver, Colorado. Mr. D'Agrosa will help expand the Company's Life Sciences business to new markets across the U.S., bringing with him more than a decade of experience in loan origination, business development, and relationship management. "We are pleased to welcome Paul to the team," said Rob Lake, Senior Managing Director of Life Sciences at Trinity Capit

    10/8/25 8:00:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Trinity Capital Inc. Expands Equipment Finance Presence to Europe with the Appointment of Brian Geraghty as Managing Director

    PHOENIX, Sept. 2, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the appointment of Brian Geraghty as Managing Director of Equipment Finance, based in Dublin, Ireland. Mr. Geraghty, with over fifteen years of experience originating loans to high-growth companies, will help drive the growth of the Company's Equipment Finance business in Europe through his deep industry knowledge and established relationships. "We are pleased to welcome Brian to our team," said Ryan Little, Senior Managing Director of

    9/2/25 8:00:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Trinity Capital Inc. Expands Tech Lending Vertical with Appointment of Josh Mackey as Director

    PHOENIX, Aug. 25, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) (the "Company"), a leading alternative asset manager, today announced the appointment of Josh Mackey, Director of Tech Lending, based in San Francisco, California. With over a decade of experience supporting innovative technology companies across the U.S., Mr. Mackey is a trusted partner within the venture ecosystem. "It is a pleasure to welcome Josh to the Trinity team," said Phil Gager, Senior Managing Director of Tech Lending at Trinity Capital. "We believe Josh's deep industry experience will further

    8/25/25 8:00:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    $RPID
    $TRIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/24 10:04:40 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    1/22/24 5:28:26 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Rapid Micro Biosystems Inc. (Amendment)

    SC 13G/A - RAPID MICRO BIOSYSTEMS, INC. (0001380106) (Subject)

    2/14/23 4:17:23 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Financials

    Live finance-specific insights

    View All

    Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

    Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas

    11/7/25 6:00:00 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Trinity Capital Inc. Reports Third Quarter 2025 Financial Results

    Record funding of $471 million Total Investment Income grows 22.3% year-over-year Net Asset Value reaches new high of $998 million PHOENIX, Nov. 5, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) ("the Company"), a leading alternative asset manager, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total investment income of $75.6 million, an increase of 22.3% year-over-year.Net investment income ("NII") of $37.0 million, or $0.52 per basic share. NII grew 25.9% year over year.Net increase in net assets

    11/5/25 8:05:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance

    Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025

    LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (NASDAQ:RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2025 financial results prior to the market open on Friday, November 7, 2025. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, November 7, 2025. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for rep

    10/28/25 5:05:00 PM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RPID
    $TRIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

    Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival (DFS), independent of radiation therapy modality utilized                                                        Company plans to initiate pivotal phase 3 clinical trial of CAN-2409 in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) and progressive disease, despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026Announced encouraging updated survival data for patients enrolled in its phase 1b clinical trial of CAN-3110 (li

    11/13/25 8:25:00 AM ET
    $CADL
    $TRIN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Finance: Consumer Services
    Finance

    Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance

    Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue. Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024.Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements. LEXINGTON, Mas

    11/7/25 6:00:00 AM ET
    $RPID
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Trinity Capital Inc. Reports Third Quarter 2025 Financial Results

    Record funding of $471 million Total Investment Income grows 22.3% year-over-year Net Asset Value reaches new high of $998 million PHOENIX, Nov. 5, 2025 /PRNewswire/ -- Trinity Capital Inc. (NASDAQ:TRIN) ("the Company"), a leading alternative asset manager, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total investment income of $75.6 million, an increase of 22.3% year-over-year.Net investment income ("NII") of $37.0 million, or $0.52 per basic share. NII grew 25.9% year over year.Net increase in net assets

    11/5/25 8:05:00 AM ET
    $TRIN
    Finance: Consumer Services
    Finance